RA patients given TNF antagonists had cancer incidences similar to other RA patients suggesting that immunosuppression may not be responsible for the cancer incidence increase and possibly pointing to severity of immune activation as the greater risk factor (Askling et al., 2005; Table 2). The gene discussed is TNF; the disease is cancer.